SCHEMBL8947206

SCHEMBL8947206

Cc1cc(O)c(/N=N/c2c(O)ccc3ccccc23)c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.58
▸ CYP2C9 P11712 2/20 0.58
▸ TSHR P16473 2/20 0.58
▸ CYP2C19 P33261 2/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ ALOX12 P18054 2/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ CSNK2A1 P68400 1/20 0.58
▸ PRMT1 Q99873 1/20 0.57
▸ MPL P40238 4/20 0.50
▸ THRB P10828 4/20 0.50
▸ CTRC Q99895 1/20 0.50
▸ GLO1 Q04760 1/20 0.47
▸ PTPRA P18433 1/20 0.45
▸ PTPRB P23467 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ RAPGEF4 Q8WZA2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21433105 0.86 CYP1A2 (0.56) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL16746724 0.84 TSHR (0.47) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL1139885 0.83 CYP1A2 (0.81) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL29407321 0.83 CYP1A2 (0.81) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL4648939 0.83 CYP1A2 (0.81) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL6003958 0.83 CYP1A2 (0.81) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL30727468 0.83 CYP1A2 (0.81) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL184949 0.82 CYP1A2 (0.80) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL184950 0.82 CYP1A2 (0.67) CYP1A2CYP2C9TSHRCYP2C19HSD17B10
SCHEMBL184951 0.82 CYP1A2 (0.80) CYP1A2CYP2C9TSHRCYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9504637-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2016-11-29 — — US disclosed
US-20160106648-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2016-04-21 — — US disclosed
US-9248086-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2016-02-02 — — US disclosed
US-20150174026-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2015-06-25 — — US disclosed
US-8932370-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2015-01-13 — — US disclosed
US-20140326269-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2014-11-06 — — US disclosed
US-8758451-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2014-06-24 — — US disclosed
US-20140013520-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2014-01-16 — — US disclosed
US-8444715-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2013-05-21 — — US disclosed
US-20120272990-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2012-11-01 — — US disclosed
US-8187340-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2012-05-29 — — US disclosed
US-20110154583-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120272990-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885
US-20110154583-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885
US-20160106648-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885
US-20140013520-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885
US-20150174026-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885
US-20140326269-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885TSHR 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback